Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Briacell Therapeutics Corp (NQ: BCTX )

6.990 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50
Open 6.990
Bid (Size) 7.180 (1)
Ask (Size) 7.230 (4)
Prev. Close 6.990
Today's Range 6.990 - 6.990
52wk Range 4.060 - 12.09
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Another BriaCell Therapeutics Goal: A Better Treatment For Prostate Cancer
A look at BriaCell's research into a better treatment for prostate cancer. 
Via Talk Markets
BriaCell Therapeutics' Mission: Destroy Breast & Prostate Cancers
From my analysis of BriaCell, it would make a great buy and hold investment. If, and when, it is bought out by a major pharmaceutical company, or brings a product directly to market itself, its stock... 
Via Talk Markets

Performance

YTD
+52.29%
+52.29%
1 Month
+1.90%
+1.90%
3 Month
+28.49%
+28.49%
6 Month
+13.29%
+13.29%
1 Year
-18.63%
-18.63%

More News

Read More
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT(TM) Combination in Advanced Metastatic Breast Cancer
Via Talk Markets
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via News Direct
Topics Death
Exposures Death
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via TheNewswire.com
Topics Death
Exposures Death
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Via Benzinga
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via TheNewswire.com
Topics Stocks
Exposures Product Safety US Equities
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via News Direct
Exposures Product Safety
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Via Benzinga
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
From ImmunoPrecise Antibodies
Via Business Wire
Why Is BriaCell (BCTX) Stock Moving Today?
Via InvestorPlace
Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Why BriaCell Therapeutics Stock Is Surging Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
Via Benzinga
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
Via FinancialNewsMedia
65 Biggest Movers From Yesterday
Via Benzinga
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
Via InvestorPlace
54 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report
Via Benzinga
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Via FinancialNewsMedia
45 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.